Latest Conference Coverage


Talking Transitional Readiness for Teens With Multiple Sclerosis: Vikram Bhise, MD

Talking Transitional Readiness for Teens With Multiple Sclerosis: Vikram Bhise, MD

November 3rd 2021

The associate professor of pediatrics and neurology at Rutgers–Robert Wood Johnson Medical School commented on the need to recognize when adolescent patients are ready to learn more about their condition. [WATCH TIME: 5 minutes]


Vikram Bhise, MD, associate professor, pediatrics and neurology; and division director, division of child neurology and neurodevelopmental disabilities, Rutgers–Robert Wood Johnson Medical School

Clinicians’ Role in Ensuring Transitional Readiness in Pediatric MS

November 2nd 2021

Vikram Bhise, MD, outlined useful questions to include in conversation when discussing the transition to adulthood for patients with pediatric multiple sclerosis.


Vikram Bhise, MD, associate professor, pediatrics and neurology; and division director, division of child neurology and neurodevelopmental disabilities, Rutgers–Robert Wood Johnson Medical School

Common Themes and Conversational Strategies for Pediatric MS Care Transition

November 1st 2021

Vikram Bhise, MD, discussed findings recently presented at CMSC 2021, where teenagers with multiple sclerosis were interviewed to identify perceptions of QOL during the transition to adulthood.


Dietitians and the Multidisciplinary MS Care Tea m: Mona Bostick, RDN, LDN, MSCS

Dietitians and the Multidisciplinary MS Care Tea m: Mona Bostick, RDN, LDN, MSCS

November 1st 2021

The founder of Food Matters 365, in Greensboro, North Carolina, commented on the benefits of adding a dietitian to the healthcare team for patients with multiple sclerosis. [WATCH TIME: 3 minutes]


Transition Readiness, Quality of Life in Pediatric Multiple Sclerosis: Vikram Bhise, MD

Transition Readiness, Quality of Life in Pediatric Multiple Sclerosis: Vikram Bhise, MD

October 29th 2021

The associate professor of pediatrics and neurology at Rutgers–Robert Wood Johnson Medical School discussed findings from a qualitative study that aimed at understanding priorities and concerns within this patient population during a transitional period.


Diet and Comorbidities in Multiple Sclerosis: Mona Bostick, RDN, LDN, MSCS

Diet and Comorbidities in Multiple Sclerosis: Mona Bostick, RDN, LDN, MSCS

October 29th 2021

The registered dietitian at Food Matters 365 in Greensboro, North Carolina, discussed the role nutrition can play in treating comorbidities, sharing her thoughts on popular elimination diets. [WATCH TIME: 2 minutes]


Addressing and Assessing Fatigue in MS From a Multidisciplinary Approach

Addressing and Assessing Fatigue in MS From a Multidisciplinary Approach

October 29th 2021

Anna Kratz, PhD, associate professor of Physical Medicine & Rehabilitation, and a research nonclinical psychologist, University of Michigan Medicine, offered insight into the multidisciplinary approach to managing fatigue for patients with multiple sclerosis.


Better COVID-19 Outcomes in MOGAD Than NMOSD, Registry Data Show

Better COVID-19 Outcomes in MOGAD Than NMOSD, Registry Data Show

October 28th 2021

Data presented at CMSC 2021 suggest worse COVID-19 outcomes were associated with patients with neuromyelitis optica spectrum disorder and other comorbidities.


Daily Spasticity Burden Represents Great Challenge for Patients With Multiple Sclerosis

Daily Spasticity Burden Represents Great Challenge for Patients With Multiple Sclerosis

October 28th 2021

In total, 72% of responders reported spasticity as a top 5 most problematic symptom, with 17% ranking it as the single most difficult symptom of MS to manage.


Promising Neuroimaging Biomarkers for Multiple Sclerosis: David Li, MD, FRCPC

Promising Neuroimaging Biomarkers for Multiple Sclerosis: David Li, MD, FRCPC

October 27th 2021

The director of the Multiple Sclerosis/MRI Research Group at the University of British Columbia spoke to some of the newer biomarkers and measures being assessed in the clinical management of multiple sclerosis. [WATCH TIME: 3 minutes]


Community Q&A: Ellen Mowry, MD, on the TREAT-MS Trial

Community Q&A: Ellen Mowry, MD, on the TREAT-MS Trial

October 27th 2021

The director of the Multiple Sclerosis Experimental Therapeutics Program at Johns Hopkins Medicine offered insight on the TREAT-MS trial to attendees of the CMSC 2021 annual meeting.


Anne H. Cross, MD, professor of neurology; and the Manny and Rosalyn Rosenthal – Dr. John Trotter MS Chair in Neuroimmunology, Washington University in St. Louis

North American, European Registry Data Show Impact of COVID-19 in Multiple Sclerosis

October 27th 2021

Data further investigated the impact of how individual disease-modifying therapies affect outcomes for this patient population.


Effects of Swank, Wahls Diets in Multiple Sclerosis: Tyler Titcomb, PhD, RDN, IFMCP

Effects of Swank, Wahls Diets in Multiple Sclerosis: Tyler Titcomb, PhD, RDN, IFMCP

October 27th 2021

The post-doctoral scholar at the University of Iowa outlined his presentation at CMSC 2021 which focused on the use of elimination diets to improve symptoms of MS. [WATCH TIME: 2 minutes]


Inadequate Medical Information Available Regarding Cannabis Use in MS

Inadequate Medical Information Available Regarding Cannabis Use in MS

October 27th 2021

All told, 48% of patients with MS reported that their most common primary person for guidance on cannabis use in MS was themself or no one, followed by a dispensary professional and MS physician.


Multiple Sclerosis MRI Protocol Card: David Li, MD, FRCPC

Multiple Sclerosis MRI Protocol Card: David Li, MD, FRCPC

October 26th 2021

The director of the Multiple Sclerosis/MRI Research Group at the University of British Columbia spoke to the portable Standardized MRI Protocol card that is being distributed in an effort to better inform the community to follow the newly published guidelines. [WATCH TIME: 2 minutes]


Induction vs Escalation for MS: Should Patients Be Started on High-Efficacy DMT?

Induction vs Escalation for MS: Should Patients Be Started on High-Efficacy DMT?

October 26th 2021

In the presidential lecture series at CMSC 2021, Ellen M. Mowry, MD, called into question whether or not the induction treatment approach in multiple sclerosis does in fact present a higher chance of preventing long-term disability.


Cortnee Romàn, FNP-C, Rocky Mountain Multiple Sclerosis Clinic and Research Group, Salt Lake City

Optimized Conversations Suggested to Improve Patient Outcomes in Multiple Sclerosis

October 26th 2021

Investigators provided 4 strategies for health care providers to implement when speaking to patients with MS, in an effort to improve communication between both parties.


Ocrelizumab Shows Similar Safety Among Older, More Disabled Patients With MS

Ocrelizumab Shows Similar Safety Among Older, More Disabled Patients With MS

October 26th 2021

Real-world data from a single-center study with more than 4 years of follow-up showed similar rates of moderate infections and malignancies to the general population with multiple sclerosis.


Brian Hutchinson, PT, MSCS, director, Multiple Sclerosis Achievement Center, Dignity Health, Sacramento

Quality of Life Improved Significantly Following Wellness Program for Multiple Sclerosis

October 25th 2021

Patient data were evaluated over a 3-year period, with analyses from baseline, year 1, and year 2 presented at previous CMSC meetings.


Swank, Wahls Diets May Reduce Fatigue and Cognitive Dysfunction in MS

Swank, Wahls Diets May Reduce Fatigue and Cognitive Dysfunction in MS

October 25th 2021

Both diets resulted in patients with MS reporting significant changes on Perceived Deficits Questionnaire scores for fatigue and cognitive dysfunction after 12 weeks of intervention.


ECTRIMS 2021: Key Takeaways, Data Highlights, and Ongoing Research

ECTRIMS 2021: Key Takeaways, Data Highlights, and Ongoing Research

October 24th 2021

The NeurologyLive staff compiled highlights from our discussions with experts in one convenient location, following ECTRIMS 2021.


Megan Weigel, DNP, APRN-C, APHN-C, MSCN, founder, First Coast Integrative Medicine

Telehealth and Integrative Medicine for Multiple Sclerosis: Megan Weigel, DNP, APRN-C, APHN-C, MSCN

October 22nd 2021

Discussing a 6-week, virtual program conducted over Zoom, the founder of First Coast Integrative Medicine, spoke on the use of telehealth and future research efforts for integrative medicine in MS. [WATCH TIME: 3 minutes]


Cleveland Clinic: Institutional Perspectives in Neurology, Chaired by Devon Conway, MD

Cleveland Clinic: Institutional Perspectives in Neurology, Chaired by Devon Conway, MD

October 22nd 2021

Chaired by Devon Conway, MD, the presentations also feature Cleveland Clinic experts Kedar Mahajan, MD, PhD; Marisa McGinley, DO; and Amy Kunchok, MD. [WATCH TIME: 1 hour, 33 minutes]


Deborah Miller, PhD, professor of neurology, Mellen Center, Cleveland Clinic

Discussing the Need for Patient Monitoring After Stopping Multiple Sclerosis Treatment

October 21st 2021

Deborah Miller, PhD, commented on strategies to maintain patient-provider communication following the discontinuation of disease-modifying therapies in MS.


Megan Weigel, DNP, APRN-C, APHN-C, MSCN, founder, First Coast Integrative Medicine

‘Inspire MS’ and Integrative Medicine for Multiple Sclerosis: Megan Weigel, DNP, APRN-C, APHN-C, MSCN

October 21st 2021

The founder of First Coast Integrative Medicine spoke on a 6-week virtual program that introduced IM modalities, including guided journaling, nutrition, and yoga. [WATCH TIME: 3 minutes]


Long-Term Ocrelizumab, Satralizumab Data Offer Insights into MS and NMOSD Care

Long-Term Ocrelizumab, Satralizumab Data Offer Insights into MS and NMOSD Care

October 20th 2021

Ashish Pradhan, MD, the executive director and disease area lead for MS and NMOSD, Genentech, offered insight on a number of presentations at the 2021 ECTRIMS Congress.


Lawrence Steinman, MD, Zimmermann Professor of Neurology and Neurological Sciences, and Pediatrics, Stanford University

Advances in MS Treatment, ECTRIMS 2021 Takeaways: Lawrence Steinman, MD

October 20th 2021

Discussing this year’s virtual ECTRIMS conference, the Zimmermann Professor of Neurology and Neurological Sciences, and Pediatrics at Stanford University provided his opinion on recent developments in the MS field. [WATCH TIME: 3 minutes]


Lawrence Steinman, MD, Zimmermann Professor of Neurology and Neurological Sciences, and Pediatrics at Stanford University

Impact of Ublituximab for Patients With Relapsing MS: Lawrence Steinman, MD

October 19th 2021

The Zimmermann Professor of Neurology and Neurological Sciences, and Pediatrics at Stanford University discussed the treatment’s potential in the multiple sclerosis space, where there are other competing drugs with similar safety profiles. [WATCH TIME: 4 minutes]

© 2025 MJH Life Sciences

All rights reserved.